I’m pleased to share a biography that reflects my journey as a global pharmaceutical and biotechnology executive across medical affairs, clinical development, regulatory strategy, and commercialization. Over the past three decades, I’ve had the opportunity to lead across respiratory, rare disease, oncology, endocrinology, infectious disease, and global market expansion while building teams, advancing innovation, and supporting product launches worldwide. Here is my biography.

I’m excited to share a deeper look into my professional journey as I transition into a new chapter focused on consulting and board advisory work. Over the past several decades, I’ve had the privilege of leading transformational initiatives, large-scale operations, regulatory programs, and technology-enabled change across RBC. I’m passionate about helping organizations navigate complexity, modernize responsibly, and create meaningful, sustainable impact. Here is my biography.

I am excited to share a deeper look into my professional journey and the experiences that have shaped my passion for regulatory leadership, pharmaceutical innovation, and organizational integrity. Throughout my 45-year career, I have had the privilege of contributing to companies, teams, and missions that advance global health and patient safety. Here is my biography.

I am excited to share my professional journey and the experiences that have shaped my approach to leadership, growth, and strategic innovation. Over the past 40 years, I have had the privilege of leading companies through transformation, commercialization, and global expansion in healthcare and medical devices. This biography highlights the milestones, insights, and lessons I have gained along the way.

I’m honored to share my professional biography, which reflects a career devoted to the development and commercialization of vaccines, anti-infectives, and diagnostics that address global microbial threats. My journey has taken me from regulatory service at the FDA to executive leadership in biotech and government programs shaping the future of infectious disease therapeutics.

After years of working across legal, regulatory, and policy roles—particularly as CEO of a financial law think tank—I’ve had the privilege of helping shape how institutions and policymakers navigate complexity in global markets. I'm driven by curiosity, a love for law and finance, and a desire to contribute meaningfully in times of change. Here is my biography.

I'm a global medical affairs leader with over two decades of experience spanning clinical research, regulatory strategy, and pharmaceutical innovation across Latin America and the United States. Throughout my career, I've had the privilege of guiding high-performing teams, launching impactful therapies, and aligning regional execution with global vision—most recently as Head of Medical Affairs for Emerging Therapy Areas at Novo Nordisk. Passionate about advancing patient outcomes and fostering collaborative leadership, I bring a strategic, people-centered approach to everything I do in the healthcare space.

After 17 years of working at the intersection of healthcare, plant science, and regulatory innovation, I’ve taken the time to reflect on the journey that’s brought me here—and where I aim to make the biggest impact next. From toxicology labs to multi-state cultivation operations, my career has been shaped by science, strategy, and a drive to lead with purpose. Here is my biography.

Susan Essumang is a seasoned clinical operations executive who merges scientific rigor with strategic leadership to drive high-impact pharmaceutical and biotech programs. Known for her patient-centric approach, Susan has led the development and regulatory success of globally recognized treatments, including Victoza®, Ozempic®, and Wegovy®, delivering billions in projected revenue. Her ability to align enterprise objectives with operational excellence has resulted in accelerated trial timelines, significant cost savings, and flawless regulatory inspections. With deep therapeutic expertise, a foundation in neuroscience and healthcare administration, and a commitment to innovation, Susan continues to shape the future of clinical research through data-driven insights and strategic execution.

Karen Martin is a seasoned expert in urban planning and entitlement strategy with over 30 years of experience guiding public and private sector projects across California. As Principal of Pacific Planning Group, Inc. and Owner of NotificationMaps.com, she has led transformative initiatives that balance regulatory precision with community-centered development. Known for her integrity, strategic insight, and collaborative leadership, Karen is now channeling her deep industry knowledge and civic commitment into board service—supporting organizations that value sustainable growth, policy expertise, and meaningful community impact.

After more than 30 years immersed in the world of cell and gene therapy, I've had the privilege to lead, innovate, and mentor across academic, clinical, and industry landscapes. From cleanroom design to regulatory submissions and teaching future leaders, my journey has been defined by purpose and progress. Here is my biography.

Susan Andros is a transformational risk and compliance leader who helps global organizations evolve responsibly by reducing risk, strengthening regulatory adherence, and leveraging technology to drive sustainable growth. With a pragmatic approach shaped by hands-on experience in dynamic financial environments, she has consistently delivered measurable results—revamping business controls, resolving complex regulatory issues, and inspiring teams to innovate. Her passion for strategic change, combined with a deep commitment to governance, customer satisfaction, and employee engagement, has made her a trusted advisor and impactful leader at some of the world’s most respected institutions.

I'm proud to share this comprehensive executive biography, which reflects my four-decade journey in global finance, risk management, corporate governance, and leadership at EY. It's been an incredible path, shaped by collaboration, innovation, and a passion for ethical impact across borders and industries.

Brian McNeill is a strategic CFO and accomplished board leader with a proven track record of transforming financial performance, strengthening governance, and driving operational excellence across the international energy sector. With more than 30 years of experience at National Grid, he has led complex business units through large-scale transformation, delivering measurable results in return on equity, cash recovery, and business growth. Recognized for his ability to align financial strategy with operational execution, Brian has played a pivotal role in accelerating the clean energy transition, integrating emerging technologies, and building diverse, high-performing teams. His expertise spans financial planning, regulatory strategy, board governance, and organizational performance, making him a trusted advisor and respected leader in navigating the evolving challenges of the global energy industry.

Michael A. Pereira is a seasoned regulatory and quality executive with over three decades of experience guiding companies through the complex intersection of FDA compliance, global regulatory standards, and business operations. Known for his ability to build and remediate Quality Management Systems across diverse healthcare sectors—including drug, device, biologic, and combination products—Michael has led strategic initiatives for startups and global enterprises alike. With a rare ability to bridge technical and business teams, he brings clarity, structure, and strategic foresight to every challenge, earning a reputation as a trusted leader and advisor in highly regulated industries.

I’m excited to share my professional journey as a financial economist, international advisor, and regulatory strategist with extensive experience in global financial governance, risk management, and policy leadership. Over the years, I’ve had the privilege of shaping key regulatory frameworks, financial standards, and economic policies that impact markets worldwide. As I transition toward board and advisory roles, I look forward to applying my expertise in governance, strategy, and cross-border finance.